Evidence map›Paper›PMID 40078327›Full record

ArticleTherapeutic advances in gastroenterology2025

Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma.

Yuko Nagaoki, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Hiroshi Aikata and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuko NagaokiDepartment of Gastroenterology, Mazda Hospital, Mazda Motor Corporation, 2-15 Aosakiminami, Fuchu-cho, Aki-gun, Hiroshima 735-8585, Japan.ORCID https://orcid.org/0000-0002-5065-2205
Kenji YamaokaDepartment of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Yasutoshi FujiiDepartment of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Shinsuke UchikawaDepartment of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Hatsue FujinoDepartment of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Atsushi OnoDepartment of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Eisuke MurakamiDepartment of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Tomokazu KawaokaDepartment of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Daiki MikiDepartment of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Hiroshi AikataDepartment of Gastroenterology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Clair Nelson HayesDepartment of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Masataka TsugeDepartment of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan Liver Center, Hiroshima University Hospital, Hiroshima, Japan.
Shiro OkaDepartment of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0002-6016-4387

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: It is not clear that antiviral therapy for hepatitis C virus (HCV) after recovery from curative treatment for hepatocellular carcinoma (HCC) has an effect on suppressing recurrence or improving survival rates. Objectives: We analyzed the impact of eradication by interferon (IFN)-free direct-acting antiviral (DAA) therapy on clinical outcomes of patients with HCV-associated HCC who underwent curative treatment. Design: This was a retrospective study. Methods: We retrospectively reviewed 109 consecutive patients with sustained virologic response with DAA therapy after HCC treatment and analyzed HCC recurrence and overall survival (OS). Among these patients are those with a history of HCC recurrence and curative HCC treatments administered as definitive HCC treatments prior to initiation of DAA therapy. Results: Among 109 patients, 64 received DAA therapy after curative treatment for HCC; the remaining 45 received ⩾2 subsequent treatments for HCC. Cumulative HCC recurrence rates at 1, 3, and 5 years were 23%, 47%, and 56%, respectively. Multivariate analysis identified predictive factors for suppression of HCC recurrence as tumor number (hazard ratio (HR) 2.293 for multiple; Conclusion: DAA therapy after curative treatment for HCC suppresses HCC recurrence in the long term, but recurrence was higher in patients with a history of many HCC treatments.

Indexed as

hepatitis C virushepatocellular carcinomaoverall survivalrecurrencesustained virologic response

Identifiers

PMID40078327
PMCPMC11898033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.